Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (12): 1057-1062.doi: 10.35541/cjd.20210568
• Guidelines and Consensus • Previous Articles Next Articles
Centre for Urticaria Research, Chinese Society of Dermatology
Received:
2021-08-06
Revised:
2021-09-26
Online:
2021-12-15
Published:
2021-12-01
Contact:
Xu Jinhua
E-mail:xjhhsyy@163.com
Centre for Urticaria Research, Chinese Society of Dermatology. Consensus on management of chronic urticaria using anti-immunoglobulin E therapy (omalizumab)[J]. Chinese Journal of Dermatology, 2021, 54(12): 1057-1062.doi:10.35541/cjd.20210568
[1] | 中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南(2018版)[J]. 中华皮肤科杂志, 2019,52(1): 1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001. |
[2] | Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update[J]. J Allergy Clin Immunol, 2014,133(5):1270⁃1277. doi: 10.1016/j.jaci.2014.02.036. |
[3] | Ulambayar B, Park HS. Anti⁃TPO IgE autoantibody in chronic urticaria: is it clinically relevant?[J]. Allergy Asthma Immunol Res, 2019,11(1):1⁃3. doi: 10.4168/aair.2019.11.1.1. |
[4] | Kaplan AP, Giménez⁃Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria[J]. Allergy, 2017,72(4):519⁃533. doi: 10.1111/all.13 083. |
[5] | Metz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI⁃positive cells in the skin[J]. Theranostics, 2017,7(5):1266⁃1276. doi: 10.7150/thno.18304. |
[6] | Serrano⁃Candelas E, Martinez⁃Aranguren R, Valero A, et al. Comparable actions of omalizumab on mast cells and basophils[J]. Clin Exp Allergy, 2016,46(1):92⁃102. doi: 10.1111/cea. 12668. |
[7] | Chan MA, Gigliotti NM, Dotson AL, et al. Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells[J]. Clin Transl Allergy, 2013,3(1):29. doi: 10.1186/2045⁃7022⁃3⁃29. |
[8] | Sánchez⁃Machín I, Iglesias⁃Souto J, Franco A, et al. T cell activity in successful treatment of chronic urticaria with omalizumab[J]. Clin Mol Allergy, 2011,9:11. doi: 10.1186/1476⁃7961⁃9⁃11. |
[9] | Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know[J]. J Allergy Clin Immunol, 2017,139(6):1772⁃1781.e1. doi: 10.1016/j.jaci.2016.08.050. |
[10] | Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria[J]. N Engl J Med, 2013,368(10):924⁃935. doi: 10.1056/NEJMoa121 5372. |
[11] | Saini SS, Bindslev⁃Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo⁃controlled study[J]. J Invest Dermatol, 2015,135(1):67⁃75. doi: 10.1038/jid.2014.306. |
[12] | Novartis Pharmaceuticals. Study of efficacy and safety of Xolair® (Omalizumab) in Chinese patients with chronic spontaneous urticaria[DB/OL]. (2020⁃11⁃04)[2021⁃10⁃08]. https://clinicaltrials.gov/ct2/show/NCT03328897. |
[13] | 张宇, 高迎霞, 顾宁琰, 等. 奥马珠单抗对慢性自发性荨麻疹患者的临床疗效和安全性分析[J]. 中华皮肤科杂志, 2021,54(7):582⁃585. doi: 10.35541/cjd.20201261. |
[14] | Metz M, Schütz A, Weller K, et al. Omalizumab is effective in cold urticaria⁃results of a randomized placebo⁃controlled trial[J]. J Allergy Clin Immunol, 2017,140(3):864⁃867.e5. doi: 10.1016/j.jaci.2017.01.043. |
[15] | Maurer M, Schütz A, Weller K, et al. Omalizumab is effective in symptomatic dermographism⁃results of a randomized placebo⁃controlled trial[J]. J Allergy Clin Immunol, 2017,140(3):870⁃873.e5. doi: 10.1016/j.jaci.2017.01.042. |
[16] | Gastaminza G, Azofra J, Nunez⁃Cordoba JM, et al. Efficacy and safety of omalizumab (Xolair) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double⁃blind and open⁃label placebo⁃controlled clinical trial[J]. J Allergy Clin Immunol Pract, 2019,7(5):1599⁃1609.e1. doi: 10.1016/j.jaip.2018.12.025. |
[17] | Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence[J]. J Allergy Clin Immunol, 2018,141(2):638⁃649. doi: 10.1016/j.jaci.2017.06.032. |
[18] | Har D, Patel S, Khan DA. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria[J]. Ann Allergy Asthma Immunol, 2015,115(2):126⁃129. doi: 10.1016/j.anai. 2015.05.010. |
[19] | Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria[J]. Allergy, 2018,73(7):1393⁃1414. doi: 10.1111/all.13397. |
[20] | Choi JH, Lee DH, Song WJ, et al. The KAAACI/KDA evidence⁃based practice guidelines for chronic spontaneous urticaria in Korean adults and children: Part 2. Management of H1⁃antihistamine⁃refractory chronic urticaria[J]. Allergy Asthma Immunol Res, 2020,12(5):750⁃770. doi: 10.4168/aair.2020.12. 5.750. |
[21] | Cox L, Platts⁃Mills TA, Finegold I, et al. American Academy of Allergy, Asthma & Immunology/american College of Allergy, Asthma And Immunology Joint Task Force Report on omalizumab⁃associated anaphylaxis[J]. J Allergy Clin Immunol, 2007,120(6):1373⁃1377. doi: 10.1016/j.jaci.2007.09.032. |
[22] | 于淼, 陈玉迪, 刘擘, 等. 中文版荨麻疹控制评分量表及信效度验证[J]. 中华皮肤科杂志, 2020,53(7):533⁃538. doi: 10. 35541/cjd.20191190. |
[23] | 于淼, 陈玉迪, 刘擘, 等. 中文版慢性荨麻疹生活质量问卷(CU⁃Q2oL)信效度验证[J]. 中华皮肤科杂志, 2020,53(12):992⁃997. doi: 10.35541/cjd.20200091. |
[24] | Curto⁃Barredo L, Spertino J, Figueras⁃Nart I, et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria[J]. Br J Dermatol, 2018,179(1):210⁃212. doi: 10.1111/bjd.16379. |
[25] | Serarslan G, Uzun M, Doğramacı AÇ, et al. Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: a retrospective study[J]. Dermatol Ther, 2019,32(1):e12752. doi: 10.1111/dth.12752. |
[26] | Ertas R, Ozyurt K, Atasoy M, et al. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change[J]. Allergy, 2018,73(3):705⁃712. doi: 10.1111/all.13345. |
[27] | Marzano AV, Genovese G, Casazza G, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients[J]. J Eur Acad Dermatol Venereol, 2019,33(5):918⁃924. doi: 10.1111/jdv.15350. |
[28] | Ferrer M, Boccon⁃Gibod I, Gonçalo M, et al. Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria[J]. Eur J Dermatol, 2017,27(5):455⁃463. doi: 10.1684/ejd.2017.3085. |
[29] | Sussman G, Hébert J, Gulliver W, et al. Omalizumab re⁃treatment and step⁃up in patients with chronic spontaneous urticaria: OPTIMA trial[J]. J Allergy Clin Immunol Pract, 2020,8(7):2372⁃2378.e5. doi: 10.1016/j.jaip.2020.03.022. |
[30] | Pinto Gouveia M, Gameiro A, Pinho A, et al. Long⁃term management of chronic spontaneous urticaria with omalizumab[J]. Clin Exp Dermatol, 2017,42(7):735⁃742. doi: 10.1111/ced. 13173. |
[31] | Alizadeh Aghdam M, Pieterse RH, Kentie PA, et al. Effective omalizumab interval prolongation in the treatment of chronic urticaria[J]. J Allergy Clin Immunol Pract, 2020,8(10):3667⁃3668.e1. doi: 10.1016/j.jaip.2020.06.056. |
[32] | Kavati A, Zhdanava M, Ortiz B, et al. Long⁃term omalizumab outcomes in chronic idiopathic urticaria: a real⁃world study[J]. Allergy Asthma Proc, 2019,40(5):321⁃328. doi: 10.2500/aap. 2019.40.4236. |
[33] | Bernstein JA, Kavati A, Tharp MD, et al. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ′real⁃world′ evidence[J]. Expert Opin Biol Ther, 2018,18(4):425⁃448. doi: 10.1080/14712598.2018.1438406. |
[34] | 奥马珠单抗治疗过敏性哮喘专家组, 中华医学会呼吸病学分会哮喘学组. 奥马珠单抗治疗过敏性哮喘的中国专家共识[J]. 中华结核和呼吸杂志, 2018,41(3):179⁃185. doi: 10.3760/cma.j.issn.1001⁃0939.2018.03.007. |
[35] | Ghazanfar MN, Thomsen SF. Successful and safe treatment of chronic spontaneous urticaria with omalizumab in a woman during two consecutive pregnancies[J]. Case Rep Med, 2015,2015:368053. doi: 10.1155/2015/368053. |
[36] | Ben⁃Shoshan M, Grattan CE. Management of pediatric urticaria with review of the literature on chronic spontaneous urticaria in children[J]. J Allergy Clin Immunol Pract, 2018,6(4):1152⁃1161. doi: 10.1016/j.jaip.2018.02.015. |
[37] | Türk M, Carneiro⁃Leão L, Kolkhir P, et al. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers[J]. J Allergy Clin Immunol Pract, 2020,8(1):113⁃124. doi: 10.1016/j.jaip.2019.07.021. |
[38] | Nettis E, Cegolon L, Di Leo E, et al. Omalizumab in elderly patients with chronic spontaneous urticaria: an Italian real⁃life experience[J]. Ann Allergy Asthma Immunol, 2018,120(3):318⁃323. doi: 10.1016/j.anai.2017.12.007. |
[39] | Agache I, Akdis C, Akdis M, et al. EAACI Biologicals Guidelines⁃Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12⁃17 years old[J/OL]. Allergy, 2021 (2021⁃07⁃29) [2021⁃10⁃08]. https://onlinelibrary.wiley.com/doi/10.1111/all.15030. doi: 10. 1111/ all.15030. [published online ahead of print]. |
[40] | Martina E, Damiani G, Grieco T, et al. It is never too late to treat chronic spontaneous urticaria with omalizumab: real⁃life data from a multicenter observational study focusing on elderly patients[J]. Dermatol Ther, 2021,34(2):e14841. doi: 10.1111/dth.14841. |
[41] | Bauer A, Dickel H, Jakob T, et al. Expert consensus on practical aspects in the treatment of chronic urticaria[J]. Allergo J Int, 2021,30(2):64⁃75. doi: 10.1007/s40629⁃021⁃00162⁃w. |
[42] | Maurer M, Giménez⁃Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria[J]. N Engl J Med, 2019,381(14):1321⁃1332. doi: 10.1056/NEJMoa1900408. |
[43] | Harris JM, Cabanski CR, Scheerens H, et al. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria[J]. J Allergy Clin Immunol, 2016, 138(6):1730⁃1732. doi: 10.1016/j.jaci.2016.06.023. |
[1] | Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2024, 57(5): 479-482. |
[2] | Guo Lan, Jin Hongzhong. Small-molecule/biological agents in the treatment of pruritus [J]. Chinese Journal of Dermatology, 2024, 57(5): 475-478. |
[3] | Ge Xinhong, Ma Yingdong, Jiao Yaning, Liu Lingling, Zhou Mei, Zi Wei, Li Bowen. Analysis of efficacy and safety of 532-nm picosecond laser in the treatment of early-stage facial seborrheic keratosis [J]. Chinese Journal of Dermatology, 2024, 57(4): 359-362. |
[4] | Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(4): 354-358. |
[5] | Liu Yi, Qu Ying, Lei Wenzhi, Liu Xiaogang, Pan Weihua, Zhang Chao. Clinical efficacy of salt-packing therapy in the treatment of pyogenic granuloma [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230553-e20230553. |
[6] | Zhang Dimin, Cao Cheng, Zhou Miaoni, Sheng Anqi, Lin Fuquan, Xu Ai′e. Analysis of disease control rate and its influencing factors in patients with progressive non-segmental vitiligo after combined treatment with compound betamethasone injection [J]. Chinese Journal of Dermatology, 2024, 57(4): 350-354. |
[7] | Zhou Tiantian, Wu Xuege, Yang Huan, Fang Xiao, Jiang Jinqiu, Chen Jingsi, Luo Xiaoyan, Wang Hua. Analysis of the etiology and factors associated with the severity of chronic spontaneous urticaria in children [J]. Chinese Journal of Dermatology, 2024, 57(4): 324-330. |
[8] | Tian Jing, Deng Sisi, Song Zhiqiang . A comparison of clinical characteristics between atopic and non-atopic prurigo nodularis [J]. Chinese Journal of Dermatology, 2024, 57(4): 331-337. |
[9] | Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus [J]. Chinese Journal of Dermatology, 2024, 57(4): 374-378. |
[10] | Ding Rui, Zhang Weiliang, Li Jing, Chen Yujia, Li Junying. Dupilumab for the treatment of five cases of refractory endogenous hyperkeratotic hand-foot eczema [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230429-e20230429. |
[11] | Song Yuqing, Yang Nan, Liu Linlin, Feng Ziyi, Han Shixin, Zhou Meijuan. Dermabrasion for the treatment of familial benign chronic pemphigus: a clinical observation of 6 cases [J]. Chinese Journal of Dermatology, 2024, 0(4): 20220278-e20220278. |
[12] | Enze LI Lu CHEN Chu-Qiao ZHANG Jiao qingqing JI Jiang. Correlations of gut microbiota and short-chain fatty acids with chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230310-e20230310. |
[13] | Yao Wo, Wang Huiying. Lanadelumab in the treatment of hereditary angioedema: a systematic review of clinical trials [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230378-e20230378. |
[14] | Li Yuanjun, Han Yuyang, Zhang Huanzhen, Wang Hui, Shen Nan, Zhang Xinglian. Dupilumab in the treatment of 12 children with chronic spontaneous urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(3): 254-257. |
[15] | Zong Yangyongyi, Ma Chujun, Su Zhonglan. Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220578-e20220578. |
|